Epizyme (EPZM) – Major News
-
Epizyme (EPZM) Acquired by Ipsen for for $1.45/sh + CVRs
-
Epizyme (EPZM) Misses Q1 EPS by 3c
-
Epizyme (EPZM) Misses Q4 EPS by 4c
-
Epizyme (EPZM) Misses Q3 EPS by 16c
-
Epizyme (EPZM) Misses Q2 EPS by 1c
-
Epizyme (EPZM) Misses Q4 EPS by 7c
-
Epizyme (EPZM) Tops Q3 EPS by 5c, Revenues Miss
-
Epizyme (EPZM) Tops Q2 EPS by 3c
-
Epizyme (EPZM) Tops Q1 EPS by 23c, Revenues Miss
-
Epizyme (EPZM) Misses Q2 EPS by 9c, Revenues Beat
-
Epizyme (EPZM) Reports Q1 Loss of $0.39/Share
-
Epizyme (EPZM) Tops Q4 EPS by 19c
-
Epizyme (EPZM) Reports Q2 Loss of $0.42
-
Epizyme (EPZM) Tops Q1 EPS by 6c
-
Epizyme (EPZM) Says U.S.-based Enrollment of New Patients into Tazemetostat Clinical Trials is Temporarily on Hold
-
Epizyme (EPZM) Tops Q4 EPS by 5c
-
Epizyme (EPZM) Tops Q1 EPS by 7c
-
Epizyme (EPZM) Tops Q4 EPS by 5c
-
Epizyme (EPZM) Tops Q3 EPS by 18c
-
Epizyme (EPZM) Tops Q2 EPS by 3c
-
Epizyme (EPZM) Tops Q1 EPS by 12c
-
Epizyme (EPZM) Tops Q4 EPS by 12c
-
Epizyme (EPZM) Tops Q3 EPS by 3c
-
Epizyme (EPZM) Tops Q2 EPS by 7c
-
Epizyme (EPZM) Issues Encouraging Update on EPZ-6438 Phase 1 in Adv. B-Cell NHL
-
Epizyme (EPZM) Misses Q1 EPS by 71c
-
Epizyme (EPZM) Tops Q4 EPS by 9c; Reacquires EZH2 Program Rights
-
Epizyme (EPZM) Misses Q3 EPS by 3c
-
Epizyme (EPZM) Tops Q2 EPS by 10c
-
Epizyme (EPZM) Posts Q1 Loss of 22c/Share
-
Epizyme (EPZM) Swings to Q4 Profit
Back to EPZM Stock Lookup
